Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | Oral combination of HMAs + venetoclax in unfit or elderly patients with AML

Farhad Ravandi • 11 Jun 2022
EHA 2022
Acute Myeloid Leukemia Leukemia Azacitidine Decitabine Venetoclax

Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the combination of hypomethylating agents (HMA) with venetoclax in elderly and unfit patients with acute myeloid leukemia (AML), commenting on the benefits of an all-oral treatment regimen in this patient population. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research funding – BMS/Celgene, Amgen, Astex/Taiho, Syros, Prelude, Abbvie, Xencor Consultant – BMS, Abbvie, Novartis, AstraZeneca, Taiho, Jazz

More from Farhad Ravandi

The combination of decitabine, venetoclax, and gilteritinib for treating AML in older adults 1:49
The combination of decitabine, venetoclax, and gilteritinib for treating AML in older adults
Farhad Ravandi • 5 Dec 2025
The potential of combining chemotherapy with allogeneic CAR-NK cells in AML: a Phase I trial 1:25
The potential of combining chemotherapy with allogeneic CAR-NK cells in AML: a Phase I trial
Farhad Ravandi • 5 Dec 2025
The efficacy and convenience of an all-oral regimen of decitabine and venetoclax in AML 2:03
The efficacy and convenience of an all-oral regimen of decitabine and venetoclax in AML
Farhad Ravandi • 11 Jun 2025
Treating older or unfit patients with AML: the current standard and future directions 4:07
Treating older or unfit patients with AML: the current standard and future directions
Farhad Ravandi • 11 Jun 2025

Related Videos

Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Genomic assessment of acquired mutations in patients with CLL treated with nemtabrutinib 3:37
Genomic assessment of acquired mutations in patients with CLL treated with nemtabrutinib
Thomas Kipps • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals